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Abstract
Background: Snakebites cause considerable death and injury throughout the globe, particularly in tropical regions,
and pose an important yet neglected threat to public health. In 2008, the Centre Anti Poison et de Parmacovigilance
du Maroc (CAPM) started to set up a specific strategy for the control of snakebites that was formalized in 2012. The aim
of the present study is to describe and update the epidemiological characteristics of snakebites notified to CAPM
between 2009 and 2013.
Methods: This retrospective five-year study included all cases of snakebites notified to CAPM by mail or phone.
Results: During the study period, 873 snakebite cases were reported to CAPM, an average incidence of 2.65 cases
per 100,000 inhabitants with 218 cases each year. The highest incidence was found in Tangier-Tetouan region
with 357 cases (40.9 %) followed by Souss Massa Draa region with 128 cases (14.6 %). The average age of patients
was 26.8 ± 17.2 years. The male to female sex ratio was 1.67:1 and 77 % of cases occurred in rural areas. The bites
occurred mainly in spring (44 %) followed by summer (42 %). Snake species was identified in 54 cases (6.2 %):
colubrids represented 31 % (n = 18) and vipers 67 % (n = 36), mainly Daboia mauritanica, Bitis arietans and
Cerastes cerastes. In 311 cases (35.6 %), the patients showed viper syndrome. Thrombocytopenia was observed
in 23.5 % of viper syndrome cases, whereas, compartment syndrome was observed in 7.6 % patients. FAV-
Afrique® was administered in 41 patients (5 %). In patients treated with antivenom, 38 patients recovered and
three died. Twenty-seven deaths were reported (3.9 %).
Conclusion: Despite specific efforts to better understand the epidemiology of snakebites in Morocco (incidence,
severity, snake species involved), it remains underestimated. Therefore, further work is still necessary to ensure
accessibility of appropriate antivenom against venomous species and to improve the management of envenomation
in Morocco.
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Background
In Morocco, the incidence of snakebite envenomation is
estimated at 0.34 per 100,000 inhabitants and case fatal-
ity rate reaches 7.2 % [1]. Although the number of
victims is elevated, it remains a neglected disease, since
it is under reported when compared to scorpion stings,
whose incidence is much higher. Usually, two snake
families are involved in accidents: seven species from the
Viperidae family are found throughout the country
(Daboia mauritanica, Bitis arietans, Cerastes cerastes,
Cerastes vipera, Echis leucogaster, Vipera latastei and
Vipera monticola), while the family Elapidae is repre-
sented by a single species, Naja haje legionis [2–4].
Regarding the type of envenomation, vipers are
responsible for the viper syndrome that associates
inflammatory and hemorrhagic disorders. Elapids are
responsible for a neurotoxic syndrome characterized
by respiratory paralysis [5]. Since 2008, the Centre
Anti Poison et de Parmacovigilance du Maroc
(CAPM) has been developing a specific strategy for
controlling snakebites. The main tasks are: implement
a specific snakebite information system for data
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collection, standardize guidelines of snakebite treat-
ment, acquire the antivenom FAV-Afrique®, which was
not available prior to 2012, train medical and para-
medical personal, and train physician toxicologists of
CAPM to identify snakes and sensitize and inform the
population. The aim of this study was to describe and
update the epidemiological characteristics of snakebite
envenomation reported to CAPM between 2009 and
2013.
Methods
This is a descriptive and retrospective study over a
period of five years (2009-2013), involving all snakebite
cases reported to CAPM. Cases were recorded by three
different forms and reporting methods established in
August 2012: Intoxication Declaration Form (IDF), In-
formation Toxicological Form (ITF) and a copy of the
specific hospital report. Only the form ITF is filled based
on phone calls from both public and health
professionals.
The statistical analysis included the frequency of bites,
age according to the International Programme on
Chemical Safety classification [6], gender, origin of the
patient (rural or urban region), season, clinical gradation,
identification of the snake species if available, and clin-
ical evolution. Patients with viper syndrome were graded
according to the following severity criteria [7]:
 Grade 0 or dry bite: moderate pain, fang marks,
without edema.
 Grade 1: severe pain, swelling not exceeding the
elbow or knee.
 Grade 2: edema exceeding the elbow or knee.
 Grade 3: edema reaching or exceeding the root
of the limb.
Snakebites were considered asymptomatic in cases
without pain and fang mark. Decrease in the number of
blood platelets (thrombocytopenia) was investigated in
case of viper syndrome. Data on coagulation tests
(WBCT, fibrinogen) are not requested routinely and very
rarely investigated. We also analyzed the cases that
received immunotherapy: FAV-Afrique® (produced by
Sanofi Pasteur, France), the only antivenom available in
Morocco since August 2012. It is a polyvalent antivenom
composed of highly purified fragments of F(ab’)2 immu-
noglobulins against ten snake species among the most
dangerous in Africa and belonging to families Viperidae
and Elapidae. The initial dose recommended is 1 to 2
vials diluted to a total of 250 milliliters in isotonic fluid
and infused over 30 to 60 min. The identification of
snakes was carried out by photos taken by physicians or
relatives of the victims who sent the images by e-mail to
CAPM or even by evaluation of the dead animal. The
initial characterization was performed by a trained toxi-
cologist physician of CAPM specialized in ophidian
identification and, then, confirmed by researchers of Rabat
Scientific Institute (Morocco). Species formally recognized
by a physician were also recorded.
Results
During the study period, 873 cases of snakebites (annual
mean of 218 cases) were notified to CAPM, showing an
average annual incidence by 2.65 cases per 100,000 in-
habitants. The highest number of cases was registered in
2013 with 336 cases (40 %) (Fig. 1). The annual variation
Fig. 1 Number of snakebites according to years, from 2009 to 2013 (data from CAPM)
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according to the regions of Morocco is specified in Table 1.
The highest annual incidence was observed in the far
north of the country in the region of Tangier-Tetouan
(13.03 cases per 100,000 population) and that of Meknes-
Tafilalet (5.46 cases per 100,000 inhabitants). In South,
Souss Massa is also a risk area and has recorded 128 cases
(3.74 cases per 100,000 inhabitants).
The mean age of the patients was 26.8 ± 17.2 years.
Adults (>15 years old) represented 55.6 % of the cases.
The male-female sex ratio was 1.67:1, and 77 % of cases
occurred in rural areas. The bites occurred mainly in
spring (44 %) and summer (42 %). June represented the
peak of bites (25.3 %) (Fig. 2).
Snakes were identified in 54 cases (6.2 %). In
20.37 % of them, the dead snake was taken to CAPM
for identification. The photo of the offending snake
was sent via e-mail to CAPM in 72.22 % of the cases
whereas the snake was formally recognized by a phys-
ician in 7.40 %. Colubrid snakes were involved in
33.4 % of the bites whereas vipers attacked 66.6 % of
the victims, namely the species Daboia mauritanica
(69.4 %), Bitis arietans (16.6 %) and Cerastes spp.
(16.6 %). Out of 873 cases of snakebites, symptoms
were specified in 502 cases (57.5 %) from which 311
cases were the viper syndrome. Sixty asymptomatic
snakebites (6.8 %) were reported, including 18 after
colubrid snakebites. Mild or severe envenomations
involved 16.4 % of Grade 0 or dry bite, 33.4 % of
Grade 1, 25.4 % of Grade 2 and 24.8 % of Grade 3.
Thrombocytopenia was observed in 23.5 % (n = 165)
and compartment syndrome in 7.6 % of cases. The overall
case fatality rate was 3.9 % (27 deaths). Souss-Massa Draa
recorded the highest number of deaths (six cases). A
higher case fatality rate occurred in children aged between
5 and 14 years (12 deaths), showing a significant death risk
[RR = 2.58; 95 % CI (1.18–5.62)].
FAV-Afrique® antivenom was administered to 41 pa-
tients (4.7 %) in doses ranging from 1 to 5 vials by
patients. The average dose administered was 1.95 vials
per patient. Among the patients treated with antivenom,
the outcome was good in 38 patients while three died.
One mild immediate adverse reaction (2.4 %) has been
reported (tachycardia). One of the cases reported to
CAPM was a 3-year-old male toddler presented to the
emergency department three hours after a snake had bit-
ten his lower right leg. He was unconscious and agitated.
His family took the dead snake to CAPM that identified
it as Daboia mauritanica. He was admitted to ICU pre-
senting Grade 3 viper syndrome, with thrombocytopenia
and anemia. He was intubated and ventilated. The brain
scan revealed a subarachnoid hemorrhage. The anti-
venom was not available locally, only a hospital 250 km
away could offer two vials of FAV-Afrique®. One vial was
given 30 h after the snakebite and another one five days
after without clinical or biological improvement. The
toddler died ten days after the snakebite.
In our study, the analysis of the clinical evolution
did not show a significant association (p > 0.05)
between the death and the administration of FAV-
Afrique® (Table 2).
Table 1 Annual incidence and mortality according to the Moroccan regions (data from CAPM, 2009–2013)





Chaouia-Ouardigha 15 1721 1 0.87 0.06 6.67
Doukala-Abda 2 2064 0 0.10 0.00 0.00
Fès-Boulemane 30 1723 4 1.74 0.23 13.33
Gharb-Chrarda-Beni Hssen 2 1982 0 0.10 0.00 0.00
Grand Casablanca 13 3855 1 0.34 0.03 7.69
Guelmim-Es Semara 20 522 1 3.83 0.19 5.00
Laayoune-Boujdour-Sakia El hamra 4 327 0 1.22 0.00 0.00
Marrakech-Tensift-Al Haouz 38 3304 5 1.15 0.15 13.16
Meknes-Tafilalt 123 2252 3 5.46 0.13 2.44
Oued Ed-Dahab-Lagouira 3 259 0 1.16 0.00 0,00
Rabat-Salé-Zemmour-Zaer 39 2695 2 1.45 0.07 5.13
Oriental 63 2003 1 3.15 0.05 1.59
Souss-Massa-Daraa 128 3421 6 3.74 0.18 4.69
Tadla-Azilal 28 1497 3 1.87 0.20 10.71
Tanger-Tetouan 357 2740 0 13.03 0.00 0.00
Taza-Al Hoceima-Taounate 5 1858 0 0.27 0.00 0.00
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Discussion
In Africa, mostly in sub-Saharan Africa, snakebite com-
prises a neglected public health problem that affects one
million people every year, resulting in 100,000 to
500,000 envenomations and 10,000 to 30,000 deaths [8].
These envenomations have an impact on morbidity due
to the abundance of snakes that affect agricultural activ-
ities, poor availability and accessibility of antivenoms [9].
In Morocco, our study showed that the average is more
than 200 snakebites per year whereas the case fatality
rate is nearly 4 %. Although far behind the scorpion stings,
envenomation by snakebites remains underestimated and
a neglected public health issue [10]. A long-term study,
between 1992 and 2007, showed of a diminished number
of notifications (100 cases per year) [11].
The creation of a control strategy in 2008 did not
significantly change the pattern of notification until
2011. However, since 2012, the number of registered
cases increased expressively (about 50 % in 2012 and up
to 150 % in 2013, compared to the years before 2012).
An increase in the number of snakebites is unlikely, es-
pecially in consecutive years. However, the formalization
of a strategy for snakebite management and awareness of
both health staff and general population, which was con-
ducted since 2012, certainly enhanced the case notification
system. It is possible that in the future more cases will
be reported.
Snakebites were predominant in rural areas, which
suggests that the risk of bites may be higher because of
more intense agricultural activities nowadays. This ob-
servation corroborates a previous study conducted by
Chippaux in sub-Saharan Africa [8]. Mainly due to their
agricultural activities, men were more afflicted with bites
than females. Similar results have been reported by
many studies in Africa and Asia [8, 9, 11, 12]. The
snakebite increased in the spring and summer, resulting
from higher activity of both snakes and humans [12, 13].
The highest incidence in Morocco’s northern regions
can be explained by better reporting of cases due to bet-
ter management of the health system. The other risk
areas are Meknès-Tafilat in the northeast and Souss
Massa Draa in the south of Morocco. This high inci-
dence could be explained by their large population, but
also by the diverse fauna of snakes found there. Further-
more, the climate in south area that varies from semiarid
to arid may play an important role in this distribution of
snakes and, therefore, snakebites.
Two families of venomous snakes are found in
Morocco: Viperidae that consists of seven species found
throughout the country – Daboia mauritanica, Bitis
arietans, Cerastes cerastes, Cerastes vipera, Echis leuco-
gaster, Vipera latastei, Vipera monticola; and family
Elapidae, represented by a single species – Naja haje
legioni [2–4, 12]. Viperidae venoms are particularly rich
in enzymes that cause inflammation, coagulation disor-
ders and necrosis. The venom of Elapidae contains
Fig. 2 Monthly distribution of snakebites (data from CAPM, 2009-2013)
Table 2 Outcome according to the administration or not of the
antivenom FAV-Afrique® (data from CAPM, 2009-2013)
Favorable Death χ2 p Relative risk Confidence
interval (95 %)
FAV Afrique®
Yes 38 3 3.34 >0.05 0.3 0.079- 1.151
No 46 12
Total 84a 15a
aTotal cases where there is information about outcome and administration
of FAV-Afrique®
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neurotoxins and phospholipases responsible for neuro-
logical effects that provoke paralysis and respiratory
failure [5].
Among the most medically important snake species
are Daboia mauritanica, Bitis arietans, and Cerastes
cerastes. Daboia mauritanica is particularly abundant
in Morocco, and the vast majority of bites reported is
attributable to this viper. Chafiq et al. [14] reported
four cases of envenomation by Daboia mauritanica.
Two cases were severe and their clinical symptoms
were characterized by thrombocytopenia, low blood
pressure, compartment syndrome, and hemorrhagic
disorder. In one of these two cases, local necrosis of
the thumb, thenar and hypothenar areas, was ob-
served and both cases were submitted to fasciotomy.
Envenomation was moderate and minor in the third
and fourth cases, respectively. No antivenom was ad-
ministered in any of these cases [14]. For other viper
species – Vipera latastei, Vipera monticola, Echis leu-
cogaster and Cerastes vipera – there are no records
of victims and they are probably less involved in bites
or not identified.
Despite a significant presence of Naja haje legionis in
Morocco, bites by this species are likely to be rare [2].
However, we cannot disregard that most neurotoxic
envenomations did not reach hospitals, as the mean
time between bite and hospital presentation is particu-
larly high. More worrying is the high case fatality rate.
It reflected a deficient management of snakebites. The
reason may be a strong under-reporting of mild cases,
inducing a reduced denominator. It can also result from
important delay of hospital presentation that affects the
effectiveness of treatment. Finally, the accessibility of
antivenom – and its adequacy – should be questioned.
The current health policy regarding the management of
envenomation recommends providing antivenom only
in hospitals of regions with high risk of snakebites.
Consequently, antivenom is not available in peripheral
health centers. Additionally, FAV-Afrique®, the only
antivenom available at the time of the study, does not
cover all species of Morocco [15, 16]. Especially two
snake species whose venom is particularly toxic and
provokes highly severe envenomation: Daboia maurita-
nica and Ceraste cerastes. Their bites represent more
than 80 % of envenomation. This would explain why
the antivenom administration did not appear to reduce
significantly the case fatality rate of viper envenomation
in Morocco.
The preparation of an appropriate antivenom is based
primarily on the selection of venoms used for the
immunization of horses to obtain the suitable antibodies
against the venom of the species present in the country
and, secondly, on the purification of therapeutic immu-
noglobulins to limit the adverse effects [17–19].
Conclusion
The specific strategy launched in 2012 had improved the
snakebite reporting system. Further efforts are required
for a better assessment of needs and an improvement of
the management of envenomation in Morocco. Currently,
actions should also be focused on the reduction of the
delay in hospital admission, sensitizing people to the prob-
lem, and accessibility to appropriate antivenom. Training
of health personnel on the use of this antivenom must be
undertaken as soon as possible.
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